NCT06143878

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Name: Clinical Trial NCT06143878
Creator: Janssen Research & Development, LLC
Keywords: Plaque Psoriasis, JNJ-77242113, Phase 3, drug, clinical trial

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Janssen Research & Development, LLC·Phase 3·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Plaque Psoriasis
Drug/Device/Intervention: JNJ-77242113
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Janssen Research & Development, LLC

Timeline & enrollment

Phase: Phase 3
Start date: Feb 09, 2024
End date: Oct 25, 2027
Enrollment: 750 participants

Primary outcome

JNJ-77242113 and Placebo Group: Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (=) 2-Grade Improvement From Baseline to Week 16,JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16

Summary

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.

ICD-10 classifications

PsoriasisLarge plaque parapsoriasisOther psoriasisSmall plaque parapsoriasisArthropathic psoriasis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06143878
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06143878 through Pure Global AI's free database. This Phase 3 trial is sponsored by Janssen Research & Development, LLC and is currently Not yet recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 750 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.